Candel Therapeutics (NASDAQ:CADL) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Candel Therapeutics (NASDAQ:CADL) from a strong sell rating to a hold rating in a report issued on Monday,Zacks.com reports.

Several other analysts have also recently commented on CADL. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen lowered Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Citigroup decreased their price objective on Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, November 14th. Finally, Stephens reaffirmed an “overweight” rating and issued a $15.00 price objective on shares of Candel Therapeutics in a research report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.00.

Candel Therapeutics Stock Performance

NASDAQ:CADL opened at $5.11 on Monday. The firm has a 50 day simple moving average of $5.63 and a 200-day simple moving average of $5.44. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.25 and a quick ratio of 8.25. The firm has a market cap of $280.54 million, a PE ratio of -8.96 and a beta of -0.91. Candel Therapeutics has a 1-year low of $4.25 and a 1-year high of $9.08.

Insider Transactions at Candel Therapeutics

In related news, Director Paul B. Manning bought 550,458 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was purchased at an average cost of $5.45 per share, for a total transaction of $2,999,996.10. Following the completion of the acquisition, the director owned 2,763,527 shares in the company, valued at $15,061,222.15. This trade represents a 24.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 16.60% of the company’s stock.

Hedge Funds Weigh In On Candel Therapeutics

A number of large investors have recently bought and sold shares of CADL. Virtu Financial LLC acquired a new position in shares of Candel Therapeutics in the 4th quarter valued at $152,000. Invesco Ltd. grew its stake in shares of Candel Therapeutics by 29.0% during the 4th quarter. Invesco Ltd. now owns 15,039 shares of the company’s stock valued at $85,000 after buying an additional 3,380 shares during the period. XTX Topco Ltd acquired a new stake in shares of Candel Therapeutics during the 4th quarter worth $134,000. Price T Rowe Associates Inc. MD raised its position in shares of Candel Therapeutics by 31.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 25,814 shares of the company’s stock worth $146,000 after buying an additional 6,176 shares during the period. Finally, Barclays PLC raised its position in shares of Candel Therapeutics by 16.4% in the 4th quarter. Barclays PLC now owns 69,344 shares of the company’s stock worth $392,000 after buying an additional 9,749 shares during the period. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.